Patents by Inventor Kenneth E. Burhop
Kenneth E. Burhop has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150005376Abstract: A concentrate esmolol formulation is provided that is safer than current concentrate (e.g., 250 mg/ml) esmolol compositions. The concentrate esmolol formulation can include from about 40-60 mg/ml of esmolol hydrochloride. The concentrate esmolol composition allows a practitioner the flexibility of choosing a bolus volume for direct injection to a patient or, optionally, to use the composition to make a customized, diluted composition of esmolol. Methods of the present invention provide for the reduction of potential adverse health consequences resulting in the improper dosing of prior art concentrate compositions of esmolol. Also, a medical product is provided that includes a concentrate esmolol housed in a container, and a package housing the container and instructions.Type: ApplicationFiled: September 12, 2014Publication date: January 1, 2015Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SAInventors: Deepak Tiwari, George Owoo, Rekha Nayak, Kenneth E. Burhop
-
Patent number: 8722736Abstract: Disclosed are concentrate esmolol injection essentially free from other related esters of esmolol and diluted esmolol compositions. The concentrate esmolol formulation includes from about 25-1000 mg/ml of esmolol and about 1-25% w/v of benzyl alcohol and the combination thereof. The compositions can also be used as multi-dose compositions. The present invention also discloses diluted, ready-to-use compositions of esmolol prepared by dilution of the present invention concentrates. Also disclosed are methods of making and using the ready-to-use compositions of the present invention.Type: GrantFiled: May 22, 2007Date of Patent: May 13, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Deepak Tiwari, George Owoo, Rekha Nayak, Kenneth E. Burhop
-
Patent number: 8426467Abstract: A concentrated esmolol formulation is provided that is distinguishable from a diluted form of the concentrated esmolol formulation.Type: GrantFiled: May 22, 2007Date of Patent: April 23, 2013Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Deepak Tiwari, George Owoo, Rekha Nayak, Kenneth E. Burhop
-
Publication number: 20080292558Abstract: A concentrated esmolol formulation is provided that is distinguishable from a diluted form of the concentrated esmolol formulation. In one embodiment, the concentrated esmolol formulation allows identification of the concentrate even after transfer of the concentrate out of a labeled primary container. The concentrated esmolol formulation can include from about 25 to about 1000 mg/ml of esmolol hydrochloride, a buffering agent and a color additive. Any number of color additives may be included such as indocyanine green, phenopheylene, hemoglobin, cyanocobalamine, patent blue, and indigo carmine vitamin B2 and naturally occurring vitamins and minerals. The amount included in the formulation is highly dependent on the color additive selected. The color additive should be included in an amount sufficient to easily distinguish the concentrated esmolol formulation from at least about a 1:4 dilution of the concentrate.Type: ApplicationFiled: May 22, 2007Publication date: November 27, 2008Inventors: Deepak Tiwari, George Owoo, Rekha Nayak, Kenneth E. Burhop
-
Publication number: 20080293814Abstract: A concentrate esmolol formulation is provided that is safer than current concentrate (e.g., 250 mg/ml) esmolol compositions. The concentrate esmolol formulation can include from about 40-60 mg/ml of esmolol hydrochloride. The concentrate esmolol composition allows a practitioner the flexibility of choosing a bolus volume for direct injection to a patient or, optionally, to use the composition to make a customized, diluted composition of esmolol. Methods of the present invention provide for the reduction of potential adverse health consequences resulting in the improper dosing of prior art concentrate compositions of esmolol. Also, a medical product is provided that includes a concentrate esmolol housed in a container, and a package housing the container and instructions.Type: ApplicationFiled: May 22, 2007Publication date: November 27, 2008Inventors: Deepak Tiwari, George Owoo, Rekha Nayak, Kenneth E. Burhop
-
Publication number: 20080293810Abstract: Disclosed are concentrate esmolol injection essentially free from other related esters of esmolol and diluted esmolol compositions. The concentrate esmolol formulation includes from about 25-1000 mg/ml of esmolol and about 1-25% w/v of benzyl alcohol and the combination thereof. The compositions can also be used as multi-dose compositions. The present invention also discloses diluted, ready-to-use compositions of esmolol prepared by dilution of the present invention concentrates. Also disclosed are methods of making and using the ready-to-use compositions of the present invention.Type: ApplicationFiled: May 22, 2007Publication date: November 27, 2008Inventors: Deepak Tiwari, George Owoo, Rekha nayak, kenneth E. Burhop
-
Patent number: 7211560Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.Type: GrantFiled: December 29, 2003Date of Patent: May 1, 2007Assignees: Baxter International, Inc., Baxter Healthcare S.A.Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
-
Publication number: 20040259769Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.Type: ApplicationFiled: December 29, 2003Publication date: December 23, 2004Applicants: Baxter International Inc., Baxter Healthcare S.A.Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
-
Patent number: 6670323Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.Type: GrantFiled: November 10, 2000Date of Patent: December 30, 2003Assignees: Baxter International, Inc., Baxter Healthcare S.A.Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
-
Patent number: 6566326Abstract: Hemoglobin chemically modified to reduce oxygen affinity and prevent dissociation are administered parenterally during resuscitation to patients suffering from burn shock. Such treatment, reduces base deficit, increases cardiac output and mean arterial blood pressure, and improves survival.Type: GrantFiled: March 13, 1996Date of Patent: May 20, 2003Assignee: The Regents of the University of CaliforniaInventors: Raluan G. Soltero, Kenneth E. Burhop, John F. Hansbrough
-
Patent number: 6458762Abstract: Administration of low doses of hemoglobin minimizes damage to the myocardium after blockage and significantly reduces reperfusion injury. Hemoglobin exerts a pharmacological effect by increasing perfusion and blocking the molecular events leading to permanent injury following an ischemic episode. Additional benefits include a reduction in the number of post-ischemic arrhythmias, reduction in the incidence of restenosis, and improved contractile function in the area of risk.Type: GrantFiled: December 2, 1994Date of Patent: October 1, 2002Assignee: Baxter International, Inc.Inventors: Jack E. McKenzie, Kenneth E. Burhop
-
Patent number: 6090779Abstract: Therapeutic treatment of septic shock comprises administering to an animal stroma-free hemoglobin, typically at a dose ranging from the least amount effective to increase perfusion, up to a dosage of about 2500 milligrams kilograms per of body weight.Type: GrantFiled: March 18, 1997Date of Patent: July 18, 2000Assignee: Baxter International, Inc.Inventors: Robert J. Przybelski, Kenneth E. Burhop
-
Patent number: 6046170Abstract: A method for treating head injury in a mammal is provided. The method comprises administering to a mammal having a head injury an effective amount of a hemoglobin preparation. A preferred hemoglobin for use in the method is diaspirin crosslinked hemoglobin.Type: GrantFiled: October 22, 1998Date of Patent: April 4, 2000Assignee: Baxter International, Inc.Inventors: Kenneth E. Burhop, Steven R. Shackford
-
Patent number: 5970985Abstract: A method for treating systemic inflammatory response syndrome in a mammal by administering to the mammal a hemoglobin preparation after the mammal is diagnosed as suffering from systemic inflammatory response syndrome, wherein the systemic inflammatory response syndrome is a condition other than sepsis.Type: GrantFiled: November 12, 1997Date of Patent: October 26, 1999Assignee: Baxter International, Inc.Inventors: Kenneth E. Burhop, Robert J. Przybelski
-
Patent number: 5877146Abstract: Administration of low doses of hemoglobin minimizes damage to the myocardium after blockage and significantly reduces reperfusion injury. Hemoglobin exerts a pharmacological effect by increasing perfusion and blocking the molecular events leading to permanent injury following an ischemic episode.Type: GrantFiled: August 7, 1995Date of Patent: March 2, 1999Assignee: Baxter International Inc.Inventors: Jack E. McKenzie, Kenneth E. Burhop
-
Patent number: 5854210Abstract: A hemoglobin preparation is administered following subarachnoid hemorrhage to dramatically reduce the tissue area of hypoperfusion and the extent of neuronal damage in the area of hypoperfusion.Type: GrantFiled: November 12, 1996Date of Patent: December 29, 1998Assignee: Baxter International Inc.Inventors: Kenneth E. Burhop, Daniel J. Cole
-
Patent number: 5804551Abstract: A method for improving recovery after surgery or an invasive procedure is provided, including administering a hemoglobin preparation to a patient before surgery or an invasive procedure.Type: GrantFiled: November 12, 1996Date of Patent: September 8, 1998Assignee: Baxter International Inc.Inventor: Kenneth E. Burhop
-
Patent number: 5733869Abstract: Administration of stroma-free crosslinked hemoglobin during standard cardiac pulmonary resuscitation procedures enhances return of spontaneous circulation following electrical defibrillation. The difficulty in restoring spontaneous circulation directly correlates with a generally poor prognosis in cases of cardiac arrest. The therapeutic effect of hemoglobin as an adjunct to conventional treatment may thereby improve survival.Type: GrantFiled: October 6, 1995Date of Patent: March 31, 1998Assignee: Baxter International, Inc.Inventors: Kenneth E. Burhop, Moses S. S. Chow